Aravive — Investor Presentation (March 2022)
48 slides from Aravive's investor presentation, Mar 3, 2022
Slide 1: Developing Transformative Targeted Cancer Therapeutics
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation March 2022 NASDAQ: ARAV
Slide 2: Forward Looking Statements
Forward Looking Statements ‘This presentation contains onward ooking statements that may discuss Aravve's plans, goals, itenions and expectations aso future tends, events, resuts of ‘operations, nancial condition or otter matters. Forward. lokang stalements general incude siatoments thal are predciv
Slide 3: Developing Transformative Targeted Cancer Therapeutics
Developing Transformative Targeted Cancer Therapeutics Batiraxcept (AVB-500): Differentiated Approach to Targeted Inhibition of GAS6/AXL Signaling Pathway Multiple Upcoming Clinical Milestones Registrational Phase 3 Trial in Platinum-Resistant Ovarian Cancer (PROC) Ongoing Phase 1b trial demonstrate
Slide 4: Experienced Management and Board of Directors
Experienced Management and Board of Directors SENIOR MANAGEMENT baa a Reshma Rangwala, MLD PRO. Viony Shah BOARD OF DIRECTORS 2020008" Chan ote Bone Decor rata Ovecee rector Draco race rector Fredtsainan. Anois, PR. Petron MD, Job near, Siw Kik Sallcinyre, Michael Ropers Erle Zhang ‘Paso. ‘ons. PhD,
Slide 5: Aravive Pipeline
Aravive Pipeline Opportunity for Expansion into Additional Indications and Drug Combinations Indication Preclinical Phase 4 Phase 2 Phase 3 Batiraxcept (AVB-500) OVARIAN CANCER Pisum Restart (oatraxcep*pacitoxe) st-Tra inEU CLEAR CELL RENAL CANCER Pte Ln (atraxcen enboranin® + (Batraxceptmanoterapy)
Slide 6: Urgent Unmet Needs & Large Market Opportunities
Urgent Unmet Needs & Large Market Opportunities pies Addressable Patients & Potential to Expand into Other Cancers and Earlier Lines Therapy Pancreatic @ vee @ « Oe en Sth leading cause of cancer A leading cause of cancer Projected 2nd leating cause of deaths among women in U.S. deaths in U.S. cance
Slide 7: Upcoming Key Milestones
Upcoming Key Milestones Updated P1b and P2.ecRCC Trial Updated Ptb Data Pancreatic Cancer Trial es Data Updated P th Pancreatic Cancer —, “Trial Data Updated P 1b ecRCC Trial — Data & Preliminary P2 Complete Enrollmentof PS ‘ecRCC Trial Data PROC (6202 hn, 0 P3PROC Top Line Results Updated P1b and P
Slide 8: GAS6/AXL Signaling Pathway
GAS6/AXL Signaling Pathway Drives Activation, Migration and Invasion of Abnormal Cells Inhibiting GAS6 Preclinically + Antitumor activity in many tumor models, including ‘ovarian, kidney, pancreatic, and breast + Blocks tumor invasion & metastasi + Overcomes acquired drug resistance + Ameliorates de
Slide 9: Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor
Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor Modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6 + ~200 fold greater affinity for human GAS6 compared to native AXL receptor + Preclinical data demonstrated relationship between aff
Slide 10: Batiraxcept (AVB-500) Inhibits Metastasis and Tumor Growth
Batiraxcept (AVB-500) Inhi its Metastasis and Tumor Growth Batiraxcept binds GAS6, preventing it from binding and activating AXL GAS$ Is the sole activating ligand of AXL m2 heron, ne re) "
Slide 11: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
Slide 12: Platinum-Resistant Ovarian Cancer Current Treatment Landscape
Platinum-Resistant Ovarian Cancer Current Treatment Landscape Need for Better Therapies: Progression-Free Survival is ~3 mos & Overall Survival ~12 mos Per current NCCN Clinical Practice Guidelines, ‘Oncology, Version 3, for Ovarian Cancer (NCCN, 2024): + For platinum-resistant disease, non-platinum
Slide 13: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies
Summary of Phase 1a Healthy Volunteer and 1b PROC Studies Phase 1a single ascending dose and repeat dose study in healthy volunteers + 43 subjects participated; 42 dosed + Batiraxcept was welltolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs + No anti-drug antibodies (ADA) + 10 mg/kg (iV) ad
Slide 14: Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure
Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure Modeling Identified RP2D of 15 mg/kg + Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile ¥y Data for Patients Receiving 10 mg/kg d 15 mg/kg of Batiraxcept & P
Slide 15: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients
Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3"+ Line of Therapy; Literature Demonstrates 85% of Patients on their 34 Line of Therapy have Progressive Disease by their First CT Scan’ PFs Month frParetcl 10 mah and 15 ma/ng AVBSOO$
Slide 16: Promising Responses in Patients in Later Lines of Therapy and <3 Month Platinum-Free Interval
Promising Responses in Patients in Later Lines of Therapy and <3 Month Platinum-Free Interval Compared to Literature Invasive Tumors Resistant to Multiple Lines of Therapy Expected to Be Dependent on the GAS6/AXL Pathway CLINICALRESPONSE CLINICALRESPONSE OF BATIRAXCEPT+ CHEMO'INPATIENTS ‘OF CHEMOTHE
Slide 17: Batiraxcept + Paclitaxel Clinical Activity in Bevacizumab Subgroups
Batiraxcept + Paclitaxel Clinical Activity in Bevacizumab Subgroups Efficacy Data for Patients Receiving 10 mg/kg and 15 mgikg of Batiraxcept & Paclitaxel + Clinical activity higher in patients who had not received Previous bevacizumab prior to entering study Bevacinumab Cubes jaive (N=0) 0 Phenomen
Slide 18: Potentially More Favorable Benefit/Risk Profile Than Competitors
Potentially More Favorable Benefit/Risk Profile Than Competitors Batiraxcept(10and 15, Compelling Anti-tumor Activity ‘mgikg cohorts)+ PAC >MinimalEfficacious, + ORR of 50% with 2 CRs, mPFS of 7.5 months, and mOS of 19 Exposure months in 10 & 15 mg/kg batiraxcept + PAC patients when trough levels ex
Slide 19: Batiraxcept Phase 3 Registrational Trial Design in PROC
Batiraxcept Phase 3 Registrational Trial Design in PROC (ClinicalTrials.gov NCT04729608) + FDA Feedback: If positive, trial could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time + Endpoint Assessment: PFS per RECIST V1.1; radiological imaging e
Slide 20: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Slide 21: ccRCC Current Treatment Landscape
ccRCC Current Treatment Landscape Initially Positioning Batiraxcept in 2L+ with Ability to Expand to 1L + Limited treatment options for patients who have failed 1L + Cabozantinib is the predominant drug used in 2L+ ccRCC* + Clinical Activity: ~ Confirmed objective response rate for (60mg) cabozantin
Slide 22: Batiraxcept + Cabozantinib Phase 1b Trial Design in ccRCC
Batiraxcept + Cabozantinib Phase 1b Trial Design in ccRCC Phase 1b Trial of Batiraxcept in Combination with Cabozantinib Population: + 26 patients + Histologically confirmed metastatic ccRCC and has progressed oniafter a front-line treatment regimen + Patients who previously were treated with caboza
Slide 23: Ph1b: Baseline Demographics
Ph1b: Baseline Demographics Representative of 2L+ ccRCC population with 100% having received prior immunotherapy Age 60 (40-81) Gender, M 22 (85%) Prior Number of Lines 1(1-5) Prior VEGF TKI 15 (58%) Prior Immunotherapy 26 (100%) IMDC Risk: Favorable 6 (23%) IMDC Risk: Intermediate/Poor 20(77%)" ne
Slide 24: Safety Profile of Batiraxcept and Cabozantinib
Safety Profile of Batiraxcept and Cabozantinib Safety Profile Consistent with the Established Safety Profile for Cabozantinib Safety Batiraxcept + Cabozar Treatment Related Deaths C) Grade 3 Adverse Events (AEs), related to 4 (15%): Events: Batiraxcept and Cabozantinib * HTN, Thrombocytopenia, throm
Slide 25: ccRCC: Clinical Activity of Batiraxcept + Cabozantinib
ccRCC: Clinical Activity of Batiraxcept + Cabozantinib + 46% best overall response rate in cabozantinib + batiraxcept group; 17-28% confirmed response rate for cabozantinib alone? ; confirmed response rates relate to PFS in 1L and 2L ecRCC? + 79% progression-free survival at 6 month; ~85-65% for cab
Slide 26: ccRCC: Pretreatment Serum sAXL/GAS6 is a Potential Biomarker
ccRCC: Pretreatment Serum sAXL/GASG is a Potential Biomarker Response Rate Increases from 46% observed in ALL patients to 63% Observed in the Biomarker High* Subgroup All Patients 15mg/kg —-20mg/kg PR for Patients with low SAXL/GAS6 0/6 (0%) 0/4 (0%) 0/2 (0%) PR for Patients with high sAXL/GAS6 12/1
Slide 27: Depth and Duration of Response in ccRCC
Depth and Duration of Response in ccRCC Batiraxcept + Cabozantinib * AsofFeb4, 2022, 5/26 (19%) have progressedor died: 107-005 103-001, 105-007, 104-001, 105-006 + Seven patients (101-004, 101-005, 102-002, 105- (002, 105-006,107-002, and 107-004) experienced resolution of one or more target lesion
Slide 28: Phase 1b/2 Trial Designed to Accelerate Development in ccRCC
Phase 1b/2 Trial Designed to Accelerate Development in ccRCC Strong Rationale to Evaluate Batiraxcept Monotherapy and Combination with Nivolumab + Cabozantinib in 1L; Initiated Enrollment in January 2022 Phase 1band Phase2Parta: Batiraxcept 15mgikg Phase 1b: Batiraxcept 20mgikg Phase2Part B: Batirax
Slide 29: Batiraxcept: Pancreatic Adenocarcinoma
Batiraxcept: Pancreatic Adenocarcinoma
Slide 30: Pancreatic Adenocarcinoma Current Treatment Landscape
Pancreatic Adenocarcinoma Current Treatment Landscape Unmet Need with Current Treatments Providing Modest Clinical Activity Gemcitabine + nab-paclitaxel used in 1L treatment for advanced pancreatic adenocarcinoma Clinical Activity’: + ORR 23% with 1 patient with CR (<1%) 20% progressed at first scan
Slide 31: Batiraxcept + gemcitabine + nab-paclitaxel Phase 1b Trial Design in 1L Pancreatic Adenocarcinoma
Batiraxcept + gemcitabine + nab-paclitaxel Phase 1b Trial Design in 1L Pancreatic Adenocarcinoma Ongoing Phase 1b Trial Phase 1b Population: Timing: * Patients (N~20) with advanced or + First patient dosed in August metastatic pancreatic 2021 Batiraxcept adenocarcinoma eligible to receive «Enrollmen
Slide 32: Initial Safety and Anti-Tumor Activity from Phase 1b Pancreatic Trial
Initial Safety and Anti Pancreatic Trial -Tumor Act ity from Phase 1b SAFETY: + No unexpected safety signals observed in the first 6 patients who completed Cycle 1 Grade 3 events related to the combination: 5 (24%). + Events include: neutropenia/neutrophil count decreased, dizziness, fatigue, muscle
Slide 33: Financial Summary
Financial Summary $67.5 Million* — 20.9 Million* No Debt Cash Runway Cash and Cash Shares Expected to Fund Equivalents Outstanding Base Operating Plan into Q4 2022* ‘tacos tatenesoatnemesneman vers Leman, 1 22022 Ne, ry 7
Slide 34: Appendix
Slide 35: Strong Biological Rationale for Batiraxcept in PROC
Strong Biological Rationale for Batiraxcept in PROC + AXL expressed in 0% (0 of 10) of normal ovarian tissue? + AXL expressed in 73% (219 of 297) ofall ovarian tumor samples, demonstrating that AXL expression is significantly higher (P < 0.0001) in ovarian carcinomas than normal ovarian epithelium?
Slide 36: Strong Biological Rationale for Batiraxcept in Pancreatic Adenocarcinoma
Strong Biological Rationale for Batiraxcept in Pancreatic Adenocarcinoma + Preclinical data demonstrated increased survival in combination with gemcitabine, decreased fibrosis, and decreased tumor weight in orthotopic models * Batiraxcept in combination with paclitaxel demonstrated compelling Clinic
Slide 37: Strong Biological Rationale for Batiraxcept in ccRCC
Strong Biological Rationale for Batiraxcept in ccRCC GASGIAXL in coRCC! + AXL plays significant role in ccRCC invasion & metastasis * AXL highly expressed in aggressive ccRCC tumors and associated with poor outcome + GASG/AXL signaling pathway is established therapeutic target to preventtreat metast
Slide 38: Batiraxcept Effectively Targets Metastasis Preclinically in ccRCC
Batiraxcept Effectively Targets Metastasis Preclinically in ccRCC Direct regulation of GAS6/AXL signaling by HIF Promotes Renal Metastasis through SRC and MET + Stress conditions in cell activate GASG/AXL signaling to allow cell to survive + Hypoxia (stress factor), typical in solid tumors, induces
Slide 39: Strong Patent Protection
Strong Patent Protection Stanford Licensed IP 4 Patent Family — Expiration 2031 us. 3 Issued Patents Worldwide: 10 Issued (2 HK Recorded) Patents (EP Validated In 18 EP Countries) 3 Pending Patent Applications Stanford-Batiraxcept Co-owned IP 3 Patent Families — Expirations 2032 / 2033 / 2035 us. 3
Slide 40: Clinical Activity of Cabozantinib in 2L+ ccRCC
Clinical Activity of Cabozantinib in 2L+ ccRCC CANTATA NCT03634540 METEOR CABOZANTINIB CABOZANTINIB + Belzutifan | CABOZANTINIB (v=223)! (W= 52) 30) Clinical Activity Objective Response % (25% Cl) 27.8 28.8(171-43.1) 47 (13-22) Complete Response (%) 1 ° ° ‘Stable Disease(%) 60 Not Reported 62 Progre
Slide 41: Summary of 1L ccRCC Preferred Regimens
SUMMARY of fL Nivolumab + ] Pembro + Asin Nivo*Cabezantinib! | Lenvatinib+Pembro! | Cabozantinls PREFERRED NCW Fplimamab (W=#32p5) (323 le) (i=385 Up) REGIMENS (escort, Keynote 426 Checkmate 9éR CLEAR Version 3.202 Invpoorn=a2s) | Cagoy 1 Conger 4 Cote 1 CheckMate 214 | (allo ooup fa ak gros) (et or
Slide 42: Summary of 2L ccRCC Preferred Regimens
SUMMARY of 2. ‘Cabozantinb Lenvatinb+ Nivolumab 30) Everoimys! (i=a0s) METEOR (ws Checkmate 02s Version 3 Gaegory Study 208 Cangoy 1 ORR (95%C) 17 a % CR) O° 2 4 PRO) 21° Eo 2m PFS (months) 7.4 48 46 (25% TRAE death (#) 1 1 0 (Grade 28 TRAES 39 (any use) 6 ‘9 (210%) Hypertension, dantes, Dantes, fab
Slide 43: Linear Regression on 1L ccRCC PFS vs ORR Demonstrates High Correlation
Linear Regression on 1L ccRCC PFS vs ORR Demonstrates High Correlation san Sommary Enarene Scineeanse Mein Fo s8a6 Seer» 9308 Someta tan : mere isan =f ko onamarr oe ssyearrannnion =e TAG ace sett ue 836-4 | amararion: yeormaere yom
Slide 44: Linear Regression on 2L and 1L+2L ccRCC PFS vs ORR Demonstrates High Correlation
Linear Regression on 2L and 1L+2L ccRCC PFS vs ORR Demonstrates High Correlation
Slide 45: Rates and Depth of Response Associated with Overall Survival in ccRCC
Rates and Depth of Response Associated with Overall Survival in ccRCC + Retrospective studies have shown that early ‘tumor shrinkage (eTS) based on target lesion reduction from baseline to first post-baseline ‘scan, has predictive value for targeted therapies in RCC (Grunwald 2015; Grunwald 2016) +
Slide 46: Strategic Collaborations
Strategic Collaborations 3DMec Exclusive license agreement for development & commercialization of batiraxcept across all oncology indications in Greater China + $12M upfront payment received + $207M total potential development and ‘commercial milestone payments; SOM development milestones achieved t
Slide 47: Potential Mechanism of Synergy Between AVB-500 and PARP Inhibitors
Potential Mechanism of Synergy Between AVB-500 and PARP Inhibitors + The association between AXL and DNA repair protein expression was reported by Balaji et al, for TNBC, NSCLC ‘and HNSCC patient cohorts, where higher AXL levels in patient tumors was associated with increased expression ‘of multiple
Slide 48: Aravive
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation March 2022 NASDAQ: ARAV